Last updated: 2026-09-16 12:10:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Cardio Diagnostics Holdings Inc. (CDIO) operates in the IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES sector and is listed on NASDAQ. The stock is currently priced at $2,04, with a market capitalisation of $6,13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,97 to $7,91. This page covers its latest market performance, valuation, price trends and company information.
$6,13M | |
$2,04 | |
$255,00 | |
$0,97 | |
$2,00 | |
7,00 | |
58,58K | |
-- | |
$7,91 | |
$0,97 | |
-- | |
-- |
Cardio Diagnostics Holdings Inc. (CDIO) is trading at $2,04 in pre-market trading as of 2026-09-16 11:14:00, up 2,20% ($0,04) from the previous close of $2,00
Pre-market trading shows how investors are pricing CDIO before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Cardio Diagnostics Holdings Inc. (CDIO) moved from $1,86 to $2,04, representing a gain of 9,89% ($0,18).
The stock traded between $1,82 and $2,16 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 36,81 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 15,5%
CDIO is currently trading at $2,04, placing it 15,5% of the way from its 52-week low of $0,97 to its 52-week high of $7,91. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
| Industry | IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES |
| Employees | 17 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Cardio Diagnostics Holdings Inc. (CDIO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.